Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
150 hedge funds and large institutions have $602M invested in Aerie Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 57 increasing their positions, 45 reducing their positions, and 20 closing their positions.
598% more call options, than puts
Call options by funds: $1.69M | Put options by funds: $242K
27% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 45
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
9% more capital invested
Capital invested by funds: $552M → $602M (+$50.4M)
1% more funds holding
Funds holding: 148 → 150 (+2)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$8.07M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$4.73M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$3.87M |
| 4 |
Morgan Stanley
New York
|
+$3.24M |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
+$3.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$14.3M |
| 2 |
Bank of New York Mellon
New York
|
-$12.8M |
| 3 |
Goldman Sachs
New York
|
-$11.3M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$9.93M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.85M |
AERI Hedge Fund Activity: Q4 2020 in Review
150 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q4 2020, worth a combined $602M — up 9.1% from $552M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new AERI positions and 20 closed out — a net gain of 2 holders — while 57 added to existing stakes and 45 trimmed.
The largest buyer was Deerfield Management, adding an estimated $8.07M. The largest seller was Franklin Resources, exiting entirely with an estimated $14.3M sold.
- 150 institutional investors held Aerie Pharmaceuticals (AERI) as of Q4 2020, up from 148 in Q3 2020.
- Funds reported $602M of Aerie Pharmaceuticals stock for Q4 2020, up 9.1% quarter-over-quarter.
- 22 funds opened new Aerie Pharmaceuticals positions in Q4 2020 and 20 closed out, a net change of +2 holders.
- The largest Aerie Pharmaceuticals buyer in Q4 2020 was Deerfield Management, an estimated $8.07M added.
- The largest Aerie Pharmaceuticals seller in Q4 2020 was Franklin Resources, an estimated $14.3M sold.
Based on aggregated 13F filings for Q4 2020.